Global Hepatitis C Disease Forecast and Market Analysis 2018-2035: Pricing is the Key Differentiator for Drugs in This Market

News provided by

Feb 15, 2018, 10:45 ET

DUBLIN, Feb. 15, 2018 /PRNewswire/ --

The "Hepatitis C Disease Forecast and Market Analysis to 2035" report has been added to ResearchAndMarkets.com's offering.

Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV). HCV belongs to the Flaviviridaevirus family, and is a communicable disease spread primarily through direct contact with the blood or the bodily fluids of an infected individual, including sexual and mother-to-child transmission. Hepatitis C infection normally does not produce signs or symptoms and, as such, most people who are infected do not know they have the disease.

Market Snapshot

Falling disease prevalence and anticipated price decreases as competition intensifies will drive a net decline in market value.
Harvoni remains the dominant option for GT-1/4 patients, but has ceded share to cheaper rivals as competition intensifies.
Cases are expected to decline, driven by complexities in high-risk populations, demographics, and treatment developments.
Mavyret's approval at a substantial discount to Epclusa paves the way for a further decline in Gilead's HCV revenues.
Lack of unmet need and declining market value prompts Johnson & Johnson and Merck & Co to discontinue pipeline regimens.
Pricing is the key differentiator for drugs in this market.

Key Topics Covered:

Forecast: Hepatitis C

Executive Summary
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Daklinza
Product Profile: Epclusa
Product Profile: Harvoni
Product Profile: Mavyret
Product Profile: Sovaldi
Product Profile: Viekira Pak Franchise
Product Profile: Vosevi
Product Profile: Ximency
Product Profile: Zepatier

Treatment: Hepatitis C

Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
Unmet Needs In Hepatitis C

Epidemiology: Hepatitis C In The Us, Japan, And 5EU

Executive Summary
Disease Overview
Sources And Methodology
Forecast
Epidemiologist Insight
Strengths And Limitations
Bibliography

Marketed Drugs: Hepatitis C

Executive Summary
Product Overview
Product Profile: Daklinza
Product Profile: Epclusa
Product Profile: Harvoni
Product Profile: Mavyret
Product Profile: Sovaldi
Product Profile: Viekira Pak Franchise
Product Profile: Vosevi
Product Profile: Ximency
Product Profile: Zepatier

Hepatitis C Pricing, Reimbursement, And Access

Executive Summary
Regulatory Labels
Payer Archetypes
Access To Recently Launched And Pipeline Products
Evidentiary Requirements And Future Pipeline Potential
Us Pricing
Us Reimbursement
Japan
Pricing In The Five Major Eu Markets
France
Germany
Italy
Spain
Uk
Methodology

Pipeline: Hepatitis C

Executive Summary
Pipeline Trends

For more information about this report visit https://www.researchandmarkets.com/research/sz2jbf/global_hepatitis?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets